Hetero, Enzene Launch India's Most Affordable Pertuzumab

Hetero Healthcare Ltd., one of the most prominent Indian pharmaceutical companies, in collaboration with Enzene Biosciences Ltd., has announced the introduction of Perzea, their cheapest biosimilar of Pertuzumab. The company hopes that this therapy for HER2-positive breast cancer will become a turning point in the journey of India to get advanced oncology treatments at an affordable price.

The introduction in the market is due to an agreement with Enzene to share the benefits of the innovation between Hetero Healthcare and the patients. The move, therefore, not only benefits the poor and marginalized but also resonates with the Government of India's agenda of universal health coverage facilitating rural and hard-to-reach areas to get access to lifesaving therapies.

Pertuzumab is a monoclonal antibody of global repute and is the best practice that is combined with trastuzumab and chemotherapy for HER2-positive breast cancer. Perzea will surely be a great help of Hetero in cutting down the costs and opening the doors of targeted therapy to thousands of Indian patients who would not have access to such treatment otherwise and thus making them an integral part of the treatment journey.

Also Read: Biocon's Yesafili Biosimilar Gains Ontario Drug Benefit Coverage

Speaking about the launch, M. Srinivas Reddy, Managing Director, Hetero Healthcare Ltd., said: "Innovation and cost-effectiveness have always been at the center of our strategy. Towards this goal, Perzea will be the most effective step to bring oncology treatments of global standards to Indian patients under budget.”

Dr. Himanshu Gadgil, CEO of Enzene Biosciences, commented: "We and Hetero are on the same track. We are both committed to technology-enabled solutions that are efficient, of a high standard, and affordable, radically transforming cancer care in India".